Selected list of NK-cell–based therapies under commercial development
| Company (in alphabetical order) . | Agent/therapy . | Trial details . |
|---|---|---|
| NK-cell therapies | ||
| Celgene | PNK-007 | Trials in AML and multiple myeloma |
| Cyto-Sen | PM21 particles: Off-the-shelf NK-cell expansion particles derived from the K562 cell line | Making good manufacturing practice material; clinical trials planned |
| Fate | FATE-NK100 (adaptive NK cells) | Trials for AML, ovarian cancer, and solid tumors with commercially available antibodies |
| NK cells derived from native and genetically modified induced pluripotent stem cells | Clinical trials planned, allowing multiple doses, off-the-shelf cryopreserved NK cells | |
| Fortress/Coronado | CNDO-109 NK-cell product | Phase 1 trial in advanced AML |
| Gamida-Cell | Nicotinamide-based NK-cell expansion (NAM-NK) | Phase 1 trial for lymphoma and multiple myeloma in combination with rituximab and elotuzumab |
| GlycoStem | Umbilical cord blood progenitor expanded NK cells | Phase 1 trial for AML, complete |
| Green Cross | MG4104 expanded random donor NK cells (no HLA matching) | Phase 1 trial including lymphoma and solid tumors |
| Miltenyi | NK-cell selection devices (CD3 and CD19 depletion and CD56 selection) | At least 12 studies listed for various cancers and combinations |
| NantKWest | NK-92 cell line–derived modified products | 5 trials for various cancers alone, gene modified, and in combinations |
| NKarta | NK-cell expansion with membrane-bound IL-15/41BB-L K562 feeders | Clinical trials in development |
| PersonGen Bio | CD33-CAR, CD19-CAR, and CD7-CAR in NK-92 cell lines | Phase 1 in AML, B-cell malignancies, and other CD7+ cancers |
| Targeted NK-cell proteins | ||
| Affimed | Tetravalent CD30-targeted CD16A engagers; other targets in development | 5 trials for lymphoma/leukemia; 1 with checkpoint combination |
| Altor Bioscience | IL-15/IL-15Ra-Fc (ALT-803) | 29 studies for various cancers, alone and in combination with NK cells, antibodies, and checkpoints |
| Bristol-Myers Squibb | Lirilumab (anti-KIR) | 9 trials for various cancers in various combinations |
| GT Pharma | CD33-targeted CD16A/CD16B engager with IL-15 linker (TriKE); other targets in development | Phase 1 trial for advanced CD33+ myeloid malignancies |
| Innate Pharma | Monalizumab (anti-NKG2A) | 3 trials for various cancers, 1 with antibody combination |
| Nektar | NKTR-255 polymer IL-15 | Clinical trials in development |
| Novartis | HetIL-15 | Phase 1 trial, alone and combination with checkpoint blockade |
| OncoMed | OMP-313M32 (anti-TIGIT) | Phase 1 trial in cancer patients |
| Tesaro | TSR-022 (anti-TIM-3) | Phase 1 trial in cancer patients |
| Company (in alphabetical order) . | Agent/therapy . | Trial details . |
|---|---|---|
| NK-cell therapies | ||
| Celgene | PNK-007 | Trials in AML and multiple myeloma |
| Cyto-Sen | PM21 particles: Off-the-shelf NK-cell expansion particles derived from the K562 cell line | Making good manufacturing practice material; clinical trials planned |
| Fate | FATE-NK100 (adaptive NK cells) | Trials for AML, ovarian cancer, and solid tumors with commercially available antibodies |
| NK cells derived from native and genetically modified induced pluripotent stem cells | Clinical trials planned, allowing multiple doses, off-the-shelf cryopreserved NK cells | |
| Fortress/Coronado | CNDO-109 NK-cell product | Phase 1 trial in advanced AML |
| Gamida-Cell | Nicotinamide-based NK-cell expansion (NAM-NK) | Phase 1 trial for lymphoma and multiple myeloma in combination with rituximab and elotuzumab |
| GlycoStem | Umbilical cord blood progenitor expanded NK cells | Phase 1 trial for AML, complete |
| Green Cross | MG4104 expanded random donor NK cells (no HLA matching) | Phase 1 trial including lymphoma and solid tumors |
| Miltenyi | NK-cell selection devices (CD3 and CD19 depletion and CD56 selection) | At least 12 studies listed for various cancers and combinations |
| NantKWest | NK-92 cell line–derived modified products | 5 trials for various cancers alone, gene modified, and in combinations |
| NKarta | NK-cell expansion with membrane-bound IL-15/41BB-L K562 feeders | Clinical trials in development |
| PersonGen Bio | CD33-CAR, CD19-CAR, and CD7-CAR in NK-92 cell lines | Phase 1 in AML, B-cell malignancies, and other CD7+ cancers |
| Targeted NK-cell proteins | ||
| Affimed | Tetravalent CD30-targeted CD16A engagers; other targets in development | 5 trials for lymphoma/leukemia; 1 with checkpoint combination |
| Altor Bioscience | IL-15/IL-15Ra-Fc (ALT-803) | 29 studies for various cancers, alone and in combination with NK cells, antibodies, and checkpoints |
| Bristol-Myers Squibb | Lirilumab (anti-KIR) | 9 trials for various cancers in various combinations |
| GT Pharma | CD33-targeted CD16A/CD16B engager with IL-15 linker (TriKE); other targets in development | Phase 1 trial for advanced CD33+ myeloid malignancies |
| Innate Pharma | Monalizumab (anti-NKG2A) | 3 trials for various cancers, 1 with antibody combination |
| Nektar | NKTR-255 polymer IL-15 | Clinical trials in development |
| Novartis | HetIL-15 | Phase 1 trial, alone and combination with checkpoint blockade |
| OncoMed | OMP-313M32 (anti-TIGIT) | Phase 1 trial in cancer patients |
| Tesaro | TSR-022 (anti-TIM-3) | Phase 1 trial in cancer patients |
Technology selected based on known developmental plan (this list does not include all technologies). Sources: clinicaltrials.gov, Innate Killer Summit San Diego 2017, and Society for Natural Immunity Annual Meeting Abstracts 2016.